Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95

Leukemia. 2017 Aug;31(8):1840-1842. doi: 10.1038/leu.2017.154. Epub 2017 May 22.

Authors

L Hinze¹, A Möricke², M Zimmermann¹, S Junk¹, G Cario², E Dagdan¹, C P Kratz¹, V Conter³, M Schrappe², M Stanulla¹

Affiliations

¹ Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
² Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany.
³ San Gerardo Hospital, Pediatric Clinic, Monza, Italy.

PMID: 28529312
DOI: 10.1038/leu.2017.154

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Asparaginase / administration & dosage
Child
Child, Preschool
Cyclophosphamide / administration & dosage
Cytarabine / administration & dosage
Daunorubicin / administration & dosage
Dexamethasone / administration & dosage*
Gene Deletion*
Humans
Ikaros Transcription Factor / genetics*
Mercaptopurine / administration & dosage
Methotrexate / administration & dosage
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Prednisone / administration & dosage
Treatment Outcome
Vincristine / administration & dosage

Substances

IKZF1 protein, human
Cytarabine
Ikaros Transcription Factor
Vincristine
Dexamethasone
Cyclophosphamide
Mercaptopurine
Asparaginase
Prednisone
Methotrexate
Daunorubicin

Supplementary concepts

AIEOP acute lymphoblastic leukemia protocol